Elanco Animal Health Inc
ELANAlpha Score of 44 reflects weak overall profile with weak momentum, strong value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 3.92M | $88.65M | NEW |
| D.E. Shaw David Shaw | 117K | $2.65M | NEW |
| Maverick Capital Lee Ainslie | 107K | $2.41M | NEW |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Susie Lee D-NV | 2022-11-30 | sale | $1k – $15k |
| Susie Lee D-NV | 2021-06-21 | purchase | $1k – $15k |
| Susie Lee D-NV | 2021-06-10 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2020-12-21 | purchase | $1k – $15k |
| Katherine M. Clark D-MA | 2020-11-05 | sale | $1k – $15k |
| Katherine M. Clark D-MA | 2020-10-22 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2020-06-16 | purchase | $1k – $15k |
| Susie Lee D-NV | 2019-12-27 | purchase | $1k – $15k |
Elanco Animal Health Incorporated is a leading global pharmaceutical company specializing in animal health. Its primary function is the development and delivery of innovative products and solutions to prevent and treat diseases in both companion animals and livestock, including dogs, cats, cattle, poultry, swine, sheep, and aquaculture species. With a heritage dating to 1954, Elanco combines six decades of research-driven expertise and operates across more than 90 countries, earning over half its revenue from international markets. The company serves veterinarians, farmers, and pet owners through a diverse portfolio that addresses significant animal health challenges, improving animal welfare while indirectly supporting food security and public health. Elanco’s ongoing commitment to research and sustainable practices positions it as a critical partner in enhancing animal well-being, supporting the agricultural sector, and advancing the global animal health industry.
Earnings calendar coming soon. Subscribe to get notified when ELAN reports next.
Get earnings alerts →